Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2023—LGC SeraCare announced the availability of its Seraseq FFPE BRCA1/2 LGR Reference Material intended for use with next-generation sequencing assays or amplified nucleic-acid–based methods that identify somatic and germline variants in BRCA1 and BRCA2 genes. The reference material contains 20 DNA variants in the genomic background of GM24385. One 10-μm formalin-fixed, paraffin-embedded curl is provided per vial.
January 2023—Spot Imaging has introduced three instruments for sample tracking and storage designed to address staffing shortages and storage inefficiencies. BlocDoc automatically captures images of cut blocks and raw slides for electronic sharing and tracking. The PathTracker scans cassettes and slide transport containers in bulk, scanning 150 cassettes in less than 25 seconds, and uploads the information to the PathTracker and laboratory information system. PathArchiv is a file-room sample management system for blocks and slides that can trace samples by case, loan status, location, or age.
January 2023—Thermo Fisher Scientific launched its TrueMark Infectious Disease Research Panels. The analytically sensitive, duplexed TaqMan assays are performed on pre-spotted and dried-down plates that include microorganism‑specific pathogens, using real‑time PCR techniques, which enables rapid and accurate detection for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases. The predefined and customizable panel options allow researchers to choose from more than 90 different bacterial and viral strain assays to generate results within four hours of taking the samples. Testing can be done from nasopharyngeal swabs or nasopharyngeal aspirate; vaginal, genital, and lesion swabs; or urine samples.
January 2023—Bio-Rad Laboratories has announced that Exact Diagnostics HBV, HCV, and HIV-1 screen controls are available in Europe. The controls are designed to monitor the performance of blood donor screening assays and are calibrated against the Third WHO International Standard for HBV (NIBSC code 10/264) and HIV-1 (10/152) and the Fourth WHO International Standard for HCV (06/102). The products are made of whole viruses in a citrate plasma matrix to ensure lot-to-lot reproducibility, have an 18-month shelf life from date of manufacture when stored at −20°C or below, and are stable for 24 hours when stored at 2° to 8°C.
February 2023—Vistapath has introduced its flagship product, the Sentinel pathology processing platform. The platform uses machine vision combined with artificial intelligence to assess specimens and create a gross report in a few seconds. It consists of the Sentinel module, which measures 17 in. W × 12 in. D × 15 in. H, and the touchscreen, which measures 15 in. W × 8 in. D × 11 in. H.
February 2023—Thermo Fisher Scientific has introduced more than 50 Absolute Q liquid biopsy assays for research use. The wet lab verified liquid biopsy assays provide highly sensitive, specific nucleic acid quantification, enabling single nucleotide polymorphisms detection down to 0.1 percent variant allele frequency.
February 2023—Werfen has received five 2022 IMV ServiceTrak clinical laboratory awards in two categories. The company received best system performance and best service awards in the coagulation analyzers category, and awards for best customer satisfaction, best system performance, and best service in the blood gas category. This is the fourth consecutive year Werfen has been recognized in coagulation and the second time it has received all three awards in the blood gas category.
January 2023—QuidelOrtho will form a joint venture between Ortho Clinical Diagnostics Trading, a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology, to develop and manufacture assays in China for QuidelOrtho’s Vitros platform. Following a successful assay pilot program, the companies expect to begin developing a broader set of assays early this year in parallel with building out the joint venture organization in the Shanghai and Beijing areas.
January 2023—StatLab has introduced the Quantum S2 automated special staining platform. The 36-slide capacity platform provides automation for more than 25 special stains, including GMS and Warthin-Starry silver stains, and uses MasterTech special stains, which produce bright, crisp, high-clarity stains, the company says.
February 2023—Qiagen announced an exclusive strategic partnership with Helix to advance companion diagnostics for hereditary diseases. Under the agreement, Qiagen will be the exclusive marketing and contracting partner in the United States for Helix’s companion diagnostic services.
